Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06961370 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 1
Development phase
132
Enrollment target
16
Study locations

NCT06961370 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 132 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (91% lower). The trial reports 16 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06961370, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 1
Development phase
132 participants
Enrollment target
16
Study locations

Study Summary

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

Conditions Studied

Age-related Macular Degeneration Geographic Atrophy

Interventions

  • DRUG RO7669330
  • DRUG Syfovre™
  • DRUG Izervay™

Study Locations (16)

Texas

  • Austin Clinical Research, LLC - Austin
  • Texas Retina Associates - Dallas
  • Retina Consultants of Texas Westover Hills Retina Center - San Antonio
  • Retina Consultants of Texas - (The Woodlands) - The Woodlands

California

  • Retina-Vitreous Associates Medical Group - Beverly Hills
  • Global Research Management - Glendale
  • Retinal Consultants Medical Group Inc - Parkcenter Drive - Sacramento

Arizona

  • Associated Retina Consultants - Phoenix - DocTrials - PPDS - Phoenix
  • Barnet Dulaney Perkins Eye Center - Sun City

Tennessee

  • Charles Retina Institute - Germantown
  • Tennessee Retina PC - Nashville

Georgia

  • Southeast Retina Center - Augusta

Maryland

  • Cumberland Valley Retina Consultants PC - Hagerstown

Missouri

  • The Retina Institute - St Louis

Oregon

  • Retina Northwest - Portland

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2025-07-16
Est. Completion 2027-01-03
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06961370

The ClinicalTrials.gov registry entry for NCT06961370 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (91% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which RO7669330 is the first listed.

NCT06961370 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06961370 about?

NCT06961370 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

What is the current status of trial NCT06961370?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-07-16. Estimated completion is 2027-01-03.

What conditions does trial NCT06961370 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.

What interventions are being tested in trial NCT06961370?

The interventions under investigation include: RO7669330 (DRUG), Syfovre™ (DRUG), Izervay™ (DRUG).

Who is sponsoring clinical trial NCT06961370?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06961370 being conducted?

This trial has 16 study locations across Arizona, California, Georgia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Age-related Macular Degeneration

All registered trials for this condition

Geographic Atrophy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.